|
Figure 1
ACY-1215 is efficacious as an anti-cancer drug in primary UM and metastatic UM cell lines. (A): Schematic diagram on the treatment regime followed. Days post treatment (dpt). (B): Representative image of clonogenic assay plates for Mel270 (top panel) and OMM2.5 cells (bottom panel) treated with 0.5% DMSO; 1, 5, 10, 20 or 50 μM ACY-1215 or 20 μM Dacarbazine for 96 h. (C,D): A dose-dependent, significant decrease in the surviving number of OMM2.5 colonies was observed, indicative of reduction in cell viability upon ACY-1215 treatment in comparison to 0.5% DMSO treatment. (E): A dose-dependent, significant decrease in OMM2.5 cell viability was observed following 96 h of ACY-1215 treatment in comparison to 0.5% DMSO treatment. (F): IC50 value of ACY-1215 in OMM2.5 cell viability assays. One-way ANOVA with Dunnett’s Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, *** p value of 0.001, **** p value of 0.0001 (N = 3–4).